Wall Street brokerages expect Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) to post earnings of ($1.21) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Alder BioPharmaceuticals’ earnings. The highest EPS estimate is ($0.83) and the lowest is ($1.98). Alder BioPharmaceuticals reported earnings per share of ($0.70) during the same quarter last year, which would indicate a negative year over year growth rate of 72.9%. The firm is scheduled to report its next earnings report on Thursday, October 26th.

On average, analysts expect that Alder BioPharmaceuticals will report full-year earnings of ($5.75) per share for the current fiscal year, with EPS estimates ranging from ($7.42) to ($4.82). For the next financial year, analysts forecast that the business will report earnings of ($4.00) per share, with EPS estimates ranging from ($6.85) to ($2.83). Zacks’ EPS calculations are an average based on a survey of analysts that cover Alder BioPharmaceuticals.

Alder BioPharmaceuticals (NASDAQ:ALDR) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.67) by $0.19. The firm had revenue of $0.68 million for the quarter. During the same quarter last year, the business posted ($0.79) EPS. The firm’s revenue for the quarter was up 518.2% on a year-over-year basis.

ALDR has been the topic of a number of research analyst reports. Needham & Company LLC set a $36.00 price objective on shares of Alder BioPharmaceuticals and gave the stock a “buy” rating in a report on Monday, July 17th. Zacks Investment Research raised shares of Alder BioPharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a report on Tuesday, July 11th. Aegis reissued a “buy” rating and set a $41.00 price objective on shares of Alder BioPharmaceuticals in a report on Wednesday, July 5th. Mizuho initiated coverage on shares of Alder BioPharmaceuticals in a report on Wednesday, September 6th. They set a “buy” rating and a $32.00 price objective on the stock. Finally, Credit Suisse Group set a $11.00 price objective on shares of Alder BioPharmaceuticals and gave the stock a “hold” rating in a report on Thursday, August 24th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $28.69.

Alder BioPharmaceuticals (NASDAQ ALDR) opened at 11.50 on Monday. The firm’s market capitalization is $778.70 million. Alder BioPharmaceuticals has a 52 week low of $8.60 and a 52 week high of $34.30. The stock’s 50 day moving average is $11.22 and its 200-day moving average is $14.18.

ILLEGAL ACTIVITY WARNING: “Analysts Expect Alder BioPharmaceuticals, Inc. (ALDR) Will Post Earnings of -$1.21 Per Share” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/10/23/analysts-expect-alder-biopharmaceuticals-inc-aldr-will-post-earnings-of-1-21-per-share.html.

In related news, insider Mark James Litton sold 16,520 shares of the company’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $12.33, for a total transaction of $203,691.60. Following the completion of the transaction, the insider now owns 116,452 shares of the company’s stock, valued at $1,435,853.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 10.60% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. Quantitative Systematic Strategies LLC acquired a new stake in shares of Alder BioPharmaceuticals in the third quarter worth $132,000. Asymmetry Capital Management L.P. increased its position in shares of Alder BioPharmaceuticals by 320.1% in the second quarter. Asymmetry Capital Management L.P. now owns 166,752 shares of the biopharmaceutical company’s stock worth $1,909,000 after acquiring an additional 127,056 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Alder BioPharmaceuticals by 1.9% in the second quarter. The Manufacturers Life Insurance Company now owns 37,488 shares of the biopharmaceutical company’s stock worth $430,000 after acquiring an additional 698 shares in the last quarter. Redmile Group LLC increased its position in shares of Alder BioPharmaceuticals by 16.4% in the second quarter. Redmile Group LLC now owns 2,223,811 shares of the biopharmaceutical company’s stock worth $25,463,000 after acquiring an additional 313,925 shares in the last quarter. Finally, State Street Corp increased its position in shares of Alder BioPharmaceuticals by 9.4% in the second quarter. State Street Corp now owns 1,944,755 shares of the biopharmaceutical company’s stock worth $22,267,000 after acquiring an additional 167,642 shares in the last quarter. 76.16% of the stock is owned by institutional investors.

Alder BioPharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Get a free copy of the Zacks research report on Alder BioPharmaceuticals (ALDR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.